KMT2A and acute myeloid leukemia: Taken together, our data revealed that A-485 exerted its anti-leukemic function in MLL-r AML through reducing H3K27Ac at the key gene loci, thereby disrupting the binding of MLL-r-BET complex to H3K27Ac (Fig. 5J) and downregulated the expression of proliferation-related genes.